GLP-1 Market
LLY $1432.29 ▲ +1.4% NVO $40.70 ▼ -1.6% PFE $29.36 ▲ +0.4% VKTX $28.66 ▼ -1.1% KLRA $14.24 ▲ +3.9% GPCR $21.73 ▲ +1.5% RHHBY $61.06 ▼ -0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

VCT220

Company
Vincentage Pharma Co., Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 11, 2026

Trial details
  • Completed NCT NCT06569355

    A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

    Not yet reported Vincentage Pharma Co., Ltd 250 participants Est. completion 2024-08-01 1 site Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06938529

    A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function

    Not yet reported Vincentage Pharma Co., Ltd 24 participants Est. completion 2025-07-25 1 site Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06939296

    A Research Study of VCT220 in Adult Chinese Participants With Obesity

    Not yet reported Vincentage Pharma Co., Ltd 840 participants Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT07011797

    A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

    Not yet reported Corxel Pharmaceuticals 250 participants Est. completion 2026-04-09 17 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT07056842

    This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole

    Not yet reported Vincentage Pharma Co., Ltd 32 participants Est. completion 2025-09-30 1 site Stand-alone
    Other conditions: Obesity &Amp; Overweight
    View official trial listing →
  • Completed NCT NCT07065058

    A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

    Not yet reported Vincentage Pharma Co., Ltd 24 participants Est. completion 2025-08-11 1 site Stand-alone
    Other conditions: Obesity &Amp; Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07340320

    A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

    Not yet reported Corxel Pharmaceuticals 251 participants Est. completion 2027-04-15 44 sites
    Other conditions: Type II Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT07347808

    A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients

    Not yet reported Vincentage Pharma Co., Ltd 16 participants Est. completion 2026-02-18 1 site Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Completed NCT NCT07349381

    A Food-Effect Study of CX11 in Healthy Participants

    Not yet reported Vincentage Pharma Co., Ltd 32 participants Est. completion 2026-08-30 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity & Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07360275

    A Study of VCT220 in Participants With Hypertension and Obesity or Overweight

    Not yet reported Vincentage Pharma Co., Ltd 160 participants Est. completion 2026-12-20 2 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Not yet recruiting NCT NCT07872436

    A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control

    Not yet reported Vincentage Pharma Co., Ltd 120 participants Est. completion 2027-09-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.